In the News

An MSK study explains how the drug selinexor, which was recently approved to treat multiple myeloma and is being tested in many other tumor types, stops cancer.

Memorial Sloan Kettering hosted its 24th annual “Thrivers” celebration to honor the patients, staff, and caregivers of the MSK Bone Marrow Transplantation (BMT) Service.

Gerstner Sloan Kettering recognizes student research by annually awarding the Grayer Fellowships, the Olayan Fellowship, the Robert B. Catell Fellowship, the Palestin Fellowship, and the Geoffrey Beene Graduate Student Fellowships.

Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer demonstrates selpercatinib’s marked antitumor activity in RET fusion-position non-small cell lung cancer (NSCLC) patients. These findings, presented by Alexander Drilon, MD, principal investigator and Research Director of Early Drug Development at Memorial Sloan Kettering Cancer Center, will form the basis of an US Food and Drug Administration new drug application submission.

A study from MSK takes a deeper look at some of the causes of secondary leukemia.

Learn what sets care for pituitary tumors apart from the rest at Memorial Sloan Kettering’s Multidisciplinary Pituitary and Skull Base Tumor Center.

Find out how parents can help children who have finished cancer treatment feel ready for school again.

Learn about MSK thoracic surgeon Valerie Rusch and her approach to treating people with lung cancer and other tumors of the chest.

The recommendation comes in the form of draft guidelines open for public comment until October 2019.

This form of cell death is called ferroptosis, and certain cancer cells are especially vulnerable to it.